WHO listed Sinopharm COVID-19 vaccine for emergency use.
On Friday, the World Health Organization (WHO) said that it had listed the China-made Sinopharm COVID-19 vaccine for emergency use.
In a news briefing in Geneva on Friday, WHO Director-General Tedros Adhanom Ghebreyesus said that the World Health Organization gave an emergency use listing to Sinopharm COVID-19 vaccine.
According to Tedros, Sinopharm was the sixth COVID-19 vaccine to receive WHO validation for efficacy, safety, and quality.
“This afternoon, WHO gave emergency use listing to Sinopharm Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality,” Tedros said.
Tedros also said that this was another COVID-19 vaccine that can be purchased by COVID-19 Vaccines Global Access (COVAX), the initiative to provide equitable global access to COVID-19 vaccines, and gave countries confidence to expedite their own regulatory approvals and imports.
WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), according to Tedros, reviewed the available data and recommended the said vaccine for adults age 18 and older with a two-dose schedule.
The other vaccines listed for emergency use by the World Health Organization were the following: Pfizer-BioNTech, AstraZeneca-Oxford, Serum Institute of India, Janssen Pharmaceuticals, and Moderna.
Prior to this, the World Health Organization (WHO) said last week that it had listed Moderna COVID-19 vaccine for emergency use.
The green light from the World Health Organization was a guideline for national regulators that a certain vaccine was effective and safe. According to Tedros, it would give countries “confidence to expedite their own regulatory approval”.
It also means that a certain vaccine can be used in the global COVAX program, which was set up last year to try to ensure fair access to vaccines among poor and rich nations.
Based on a report on BBC News, the decision to list China’s Sinopharm COVID-19 vaccine for emergency use was expected to give a substantial boost to the scheme, which had been struggling with supply problems.